peginterferon alfa-2b

Ligand id: 7462

Name: peginterferon alfa-2b

No information available.
Summary of Clinical Use
Initially introduced as an antiviral medication to treat hepatitis C. More recently (2011) the US FDA authorised peginterferon alfa-2b (as Sylatron®) to treat melanoma following surgical tumour resection.
Mechanism Of Action and Pharmacodynamic Effects
PEG-interferon alpha-2b acts as a multifunctional immunoregulatory cytokine. Transcription of many genes (involved in cell cycle control, cell differentiation, apoptosis, and immune response) is activated by the interferon stimulated transcription factor-3 (ISGF3), which forms downstream of PEG-interferon alpha-2b-induced interferon-alpha receptor 1 and 2 (IFNAR1/2) activation of the JAK/STAT signalling pathway [2]. The clinical outcome is improved immune response and apoptosis of malignant cells [1].
External links